Австралия - английский - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 10 mg - injection, solution - excipient ingredients: phenol; poloxamer; sodium hydroxide; phosphoric acid; monobasic sodium phosphate dihydrate; dibasic sodium phosphate heptahydrate; water for injections; glycine - omnitrope is intended for the long term treatment of children (above three years of age) with, growth disturbance due to insufficient secretion of pituatary growth hormone, growth disturbance associated with gonadal dysgenesis (turner syndrome), growth disturbance associated with chronic renal insufficiency.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 3.3 mg/ml - injection - excipient ingredients: poloxamer; dibasic sodium phosphate heptahydrate; benzyl alcohol; sodium hydroxide; monobasic sodium phosphate; mannitol; water for injections; phosphoric acid - omnitrope is intended for long term treatment of children (above three years of age with growth disturbance due to insufficient secretion of pituitary growth hormone; growth disturbance associated with gonadal dysgenesis (turner's syndrome); & growth disturbance associated with chronic renal insufficiency.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; phenol; phosphoric acid; water for injections; sodium chloride; monobasic sodium phosphate dihydrate; dibasic sodium phosphate heptahydrate; poloxamer - omnitrope is intended for the long term treatment of children (above three years of age) with:,- growth disturbance due to insufficient secretion of pituitary growth hormone,- growth disturbance associated with gonadal dysgenesis (turner syndrome),- growth disturbance associated with chronic renal insufficiency.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

scigen australia pty ltd - somatropin, quantity: 6.67 mg/ml - injection, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; monobasic sodium phosphate dihydrate; poloxamer; phenol; glycine; phosphoric acid; sodium hydroxide; water for injections - omnitrope is intended for the long term treatment of children (above three years of age) with, growth disturbance due to insufficient secretion of pituatary growth hormone, growth disturbance associated with gonadal dysgenesis (turner syndrome), growth disturbance associated with chronic renal insufficiency.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 10 mg - injection, solution - excipient ingredients: phenol; poloxamer; sodium hydroxide; phosphoric acid; monobasic sodium phosphate dihydrate; dibasic sodium phosphate heptahydrate; water for injections; glycine - omnitrope is intended for the long term treatment of children (above three years of age) with, growth disturbance due to insufficient secretion of pituatary growth hormone, growth disturbance associated with gonadal dysgenesis (turner syndrome), growth disturbance associated with chronic renal insufficiency.

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - somatropin 5.8mg equivalent to 5 mg somatropin (after reconstitution) - powder for injection - 5 mg - active: somatropin 5.8mg equivalent to 5 mg somatropin (after reconstitution) excipient: dibasic sodium phosphate glycine mannitol monobasic sodium phosphate mannitol metacresol water for injection - adults replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in two different dynamic tests for growth hormone deficiency. patients must also fulfill the following criteria. childhood onset: patients, who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with genotropin miniquick is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. prader-willi syndrome, for improvement of body composition.

Соединенные Штаты - английский - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl) - somatropin 5 mg in 1 ml - genotropin is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone. genotropin is indicated for the treatment of pediatric patients who have growth failure due to prader-willi syndrome (pws). the diagnosis of pws should be confirmed by appropriate genetic testing [see contraindications (4)] . genotropin is indicated for the treatment of growth failure in children born small for gestational age (sga) who fail to manifest catch-up growth by age 2 years. genotropin is indicated for the treatment of growth failure associated with turner syndrome. genotropin is indicated for the treatment of idiopathic short stature (iss), also called non-growth hormone-deficient short stature, defined by height standard deviation score (sds) ≤-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other c

Соединенные Штаты - английский - NLM (National Library of Medicine)

genentech, inc. - somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl) - somatropin 10 mg in 2 ml - growth hormone deficiency (ghd) - nutropin aq® is indicated for the treatment of pediatric patients who have growth failure due to inadequate secretion of endogenous growth hormone (gh). growth failure secondary to chronic kidney disease (ckd) - nutropin aq is indicated for the treatment of growth failure associated with ckd up to the time of renal transplantation. nutropin aq therapy should be used in conjunction with optimal management of ckd. idiopathic short stature (iss) - nutropin aq is indicated for the treatment of iss, also called non-ghd short stature, defined by height sds ≤ –2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means. short stature associated with turner syndrome (ts) - nutropin aq is indicated for the treatment of short stature associated wit

Ирландия - английский - HPRA (Health Products Regulatory Authority)

novo nordisk a/s - somatropin - solution for injection in pre-filled pen - 10/1.5 milligram(s)/millilitre - somatropin and somatropin agonists; somatropin

Ирландия - английский - HPRA (Health Products Regulatory Authority)

novo nordisk a/s - somatropin - solution for injection in pre-filled pen - 5/1.5 milligram(s)/millilitre - somatropin and somatropin agonists; somatropin